The Enzymotec Ltd. (ENZY) Upgraded to Hold by Zacks Investment Research

The Enzymotec Ltd. (ENZY) Upgraded to Hold by Zacks Investment Research

Zacks Investment Research upgraded shares of Enzymotec Ltd. (NASDAQ:ENZY) from a sell rating to a hold rating in a report issued on Tuesday.

According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “

Several other equities analysts also recently issued reports on ENZY. Jefferies Group restated a hold rating and set a $7.00 price objective (down previously from $8.00) on shares of Enzymotec in a report on Monday, November 28th. Wells Fargo & Company downgraded shares of Enzymotec from an outperform rating to a market perform rating in a report on Thursday, November 17th.

Shares of Enzymotec (NASDAQ:ENZY) traded down 0.64% on Tuesday, hitting $7.80. 15,312 shares of the company traded hands. The firm has a market capitalization of $177.52 million, a P/E ratio of 72.90 and a beta of 1.19. The firm’s 50-day moving average is $6.68 and its 200 day moving average is $7.30. Enzymotec has a 1-year low of $5.20 and a 1-year high of $10.00.

Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings data on Wednesday, November 16th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.04. Enzymotec had a net margin of 4.82% and a return on equity of 1.95%. The company had revenue of $11.40 million for the quarter, compared to analyst estimates of $13.29 million. During the same quarter last year, the company earned $0.08 EPS. The business’s revenue was down 8.1% compared to the same quarter last year. On average, analysts anticipate that Enzymotec will post $0.18 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the company. Van ECK Associates Corp increased its position in shares of Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock valued at $106,000 after buying an additional 706 shares during the period. TFS Capital LLC acquired a new position in shares of Enzymotec during the second quarter valued at $153,000. State of New Jersey Common Pension Fund D increased its position in shares of Enzymotec by 13.5% in the third quarter. State of New Jersey Common Pension Fund D now owns 24,997 shares of the company’s stock valued at $175,000 after buying an additional 2,976 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Enzymotec by 12.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 21,313 shares of the company’s stock valued at $178,000 after buying an additional 2,298 shares during the period. Finally, Icon Advisers Inc. Co. increased its position in shares of Enzymotec by 87.0% in the third quarter. Icon Advisers Inc. Co. now owns 31,417 shares of the company’s stock valued at $220,000 after buying an additional 14,617 shares during the period. Institutional investors own 35.93% of the company’s stock.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Get a free copy of the Zacks research report on Enzymotec (ENZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment